Evra Patche 3 Patches

Description

EVRA contains two types of sex hormones, a progestogen called norelgestromin and an oestrogen called ethinyl estradiol. Because it contains two hormones, EVRA is called a ‘combined hormonal contraceptive’. It is used to prevent pregnancy. How to use How many patches to use Weeks 1, 2 and 3: Put one patch on and leave it on for exactly seven days. Week 4: Do not put a patch on this week. If you did not use hormonal contraception during your previous cycle You can start this medicine on the first day of your next period. If it has been a day or more since your period started, talk to your doctor about temporarily using a non-hormonal contraceptive. If you are switching from oral contraceptive pills to the transdermal patch If you are switching from oral contraceptive pills to this medicine: Wait until you get your period. Apply the first patch within the first 24 hours of your period. If the patch is applied after the first day of your period, you should: Use a non-hormonal method of contraception until the 8th day when you change the patch. If you do not get your period within 5 days of taking your last pill, consult your doctor before starting this medicine. Warnings and precautions Before using this medicine, you will need to see your doctor for a medical check‑up. During clinical trials with patients treated for hepatitis C virus infections (HCV) with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequent in women using ethinylestradiolcontaining medications such as combined hormonal contraceptives (CHCs). ALT elevations have also been observed with HCV anti-viral medicinal products containing glecaprevir/ pibrentasvir and sofosbuvir/ velpatasvir/ voxilaprevir. Side Effects If you experience any of the following symptoms you should contact your doctor or go to the hospital straight away: Very common side effects (may affect more than 1 in 10 women): Headache Nausea Breast tenderness. Common side effects (may affect up to 1 in 10 women): Vaginal yeast infection, sometimes called thrush Mood problems such as depression, change in mood or mood swings, anxiety, crying Dizziness Migraine Stomach ache or bloating Vomiting or diarrhoea Acne, skin rash, skin itching or skin irritation Muscle spasms Breast problems such as pain, enlargement or lumps in the breast Changes in menstrual bleeding pattern, uterine cramps, painful periods, vaginal discharge Problems where the patch has been on the skin such as redness, irritation, itching or rash Feeling tired or generally unwell Weight gain. Storage Information Store in the original container to protect from light and moisture. Do not store above 30 ºC. Do not refrigerate or freeze. Drug Interactions Certain medicines and herbal therapies may stop EVRA from working properly. If this happens you could get pregnant, or may experience unexpected bleeding. These include medicines used for the treatment of: Some antiretroviral medicines used to treat HIV/AIDS and Hepatitis C virus infections (so-called protease inhibitors and non‑nucleoside reverse transcriptase inhibitors such ritonavir, nevirapine, efavirenz)) Medicines for infection (such as rifampicin and griseofulvin) Anti‑seizure medicines (such as barbiturates, topiramate, phenytoin, carbamazepine, primidone, oxcarbazepine, and felbamate) Bosentan (a medicine for high blood pressure in the blood vessels in the lungs) St. John’s wort (an herbal therapy used for depression) Ingredients The active substances are norelgestromin and ethinyl estradiol. The other ingredients are: backing layer: low-density pigmented polyethylene outer layer, polyester inner layer; middle layer: polyisobutylene/polybutene adhesive, crospovidone, non-woven polyester fabric, lauryl lactate; third layer: polyethylene terephthalate (PET) film, polydimethylsiloxane coating. Specifications EVRA is a thin, beige, plastic transdermal patch stamped “EVRA”. The sticky adhesive side is stuck to the skin after removal of the clear, plastic, protective covering.